Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

Item

http://www.wikidata.org/entity/Q34413664

Q34413664

about

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients Management of relapsed ovarian cancer: a review Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials Bevacizumab in ovarian cancer: A critical review of phase III studies Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics Assessing the in vivo efficacy of doxorubicin loaded hyaluronan nanoparticles.Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.Major clinical research advances in gynecologic cancer in 2010 SEOM guideline in ovarian cancer 2014.Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy - General mapping algorithms Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012.SEOM Clinical Guideline in ovarian cancer (2016)Recurrent ovarian cancer: when and how to treat.Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.The changing landscape of therapeutic strategies for recurrent ovarian cancer.Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.The next steps in improving the outcomes of advanced ovarian cancer.An overview of early investigational therapies for chemoresistant ovarian cancer.Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?The efficacy of trabectedin in treating ovarian cancer.Recurrent ovarian cancer.Discussion: session 1.Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study.Effective treatment of a patient with stage IV ovarian cancer: A case report.Optimizing treatment in recurrent epithelial ovarian cancer.Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project.Platinum or nonplatinum in recurrent ovarian cancer: that is the question.The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer.

P2860

Q24201282-A9FC0B03-B3FF-4F42-AA40-55184724FA41 Q24633820-6F765D67-552C-47C6-9365-C341BE0A0BD7 Q26741755-50B6E1E0-BBEA-4E12-B696-A8C54CE18FD8 Q26858830-780CAAAE-0606-4078-B098-75519C90F30C Q28076188-F8248D0A-6330-45BF-996B-E8A0541CF0B7 Q28083801-DCD05A75-BCF0-439E-AA1A-04AF283C02CC Q30421664-BAA45C02-0C17-4AB9-980F-1B63CC584B6B Q30570691-94AF5603-FC70-486F-A451-8532C9AB7EA6 Q33921802-714498CB-6848-40FB-A9DF-D701F4F59143 Q34413670-DBAE6243-8078-4373-84D0-50CF5F9A7349 Q34517694-B8D51D9D-DDFB-4A62-B514-F0961F318ABD Q34553508-A5246273-68F1-49F9-9616-97E99B64EDB4 Q34996149-57D875F3-A0C3-41DE-AE24-7E7E3B14866B Q36332234-12602AAC-FA9F-4788-A8C0-88E82EAFA31F Q36382345-542D1BFC-CAC4-4E4F-8B7F-1FA0362AFC11 Q36728989-49C3395D-1ED9-4585-AE43-4F0FD4FC4FA1 Q36962482-5139A226-16C9-42A9-83FC-F5D577E6DBA2 Q37475168-C6559565-3804-499F-A41A-49CA09788081 Q37951860-D856D29E-7155-4A32-BE4F-1CA509341393 Q37964713-9F5645DF-91C5-40F1-9D7F-D1895504F950 Q37965631-CD49DCE5-844E-40BC-87D1-B43D7A751B77 Q38048887-A3DEA03C-27B5-4694-ABF8-11CD8103B733 Q38160258-65E81D80-B325-4376-8422-E1660E24EC4E Q38535374-600A926C-BBE0-4B1B-ACC1-3E5143B047E9 Q38553247-CE6471E5-80B8-4555-8296-6240E858BE69 Q38693066-7546D1F1-E815-435A-8E28-839F0A5D91E5 Q38763841-E6248C57-F490-423F-A83D-B432E24B23EC Q38872230-BC351FC7-F972-4D8A-BBE4-637E9D394CCA Q39316221-1A389CA2-87BD-425E-BD4E-721033435EAA Q44616736-6A600373-961B-46D7-A5BF-93281F34A8C8 Q47106566-2E3373CB-6805-454D-93E7-E16FE9BBFC1B Q47549019-E516998E-6834-47B9-A89F-38AE5755C732 Q47885855-FF010D96-18B0-4F43-8C3A-194E99038A67 Q47903289-26CF4DFF-38CC-400F-9CBF-AD999D573809 Q50677312-920F716D-3609-430C-9276-3E3A0DE01488

P2860

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

Item

http://www.wikidata.org/entity/Q34413664

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Trabectedin plus pegylated lip ...... 301 phase III randomized trial

@ast

Trabectedin plus pegylated lip ...... 301 phase III randomized trial

@en

Trabectedin plus pegylated lip ...... e partially platinum-sensitive

@nl

type

Item

label

Trabectedin plus pegylated lip ...... 301 phase III randomized trial

@ast

Trabectedin plus pegylated lip ...... 301 phase III randomized trial

@en

Trabectedin plus pegylated lip ...... e partially platinum-sensitive

@nl

prefLabel

Trabectedin plus pegylated lip ...... 301 phase III randomized trial

@ast

Trabectedin plus pegylated lip ...... 301 phase III randomized trial

@en

Trabectedin plus pegylated lip ...... e partially platinum-sensitive

@nl

P1476

Trabectedin plus pegylated lip ...... 301 phase III randomized trial

@en

P2093

A Poveda

http://www.w3.org/2001/XMLSchema#string

B J Monk

http://www.w3.org/2001/XMLSchema#string

B Kong

http://www.w3.org/2001/XMLSchema#string

C Lebedinsky

http://www.w3.org/2001/XMLSchema#string

E Filipczyk-Cisarz

http://www.w3.org/2001/XMLSchema#string

H Hagberg

http://www.w3.org/2001/XMLSchema#string

I Vergote

http://www.w3.org/2001/XMLSchema#string

J Gómez

http://www.w3.org/2001/XMLSchema#string

M Roy

http://www.w3.org/2001/XMLSchema#string

N Colombo

http://www.w3.org/2001/XMLSchema#string

P2860

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.

Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.

Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance.

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

Management of platinum-sensitive recurrent ovarian cancer.

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.

Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy.

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.

P304

39-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDQ352

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Vicente Alfaro

P577

2010-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45275029

http://www.w3.org/2001/XMLSchema#string

P698

20643862

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

phase III clinical trial

P932

3003616

http://www.w3.org/2001/XMLSchema#string

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

about

P2860

P2860

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932